SEC Form 4 · accession 0001209191-17-044104
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 3, 2017 | M | 3,438 | $73.51 | A | 125,949 | D | |
| Common StockF2,F3 | Jul 3, 2017 | S | 2,222 | $127.38 | D | 123,727 | D | |
| Common StockF2,F4 | Jul 3, 2017 | S | 1,216 | $128.57 | D | 122,511 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $73.51 | Jul 3, 2017 | M | 3,438 | D | — | Jan 1, 2024 | Common Stock | 3,438 | 6,875 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Mr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $127.38 (range $126.99 to $127.89).
- F4Open market sales reported on this line occurred at a weighted average price of $128.57 (range $128.19 to $129.05).
- F5The option vests in 16 quarterly installments from 01/02/2014.